The iconic Apollo Theater in Harlem is preparing to go dark for more than a year, as crews get ready to begin the venue’s first large-scale renovation in its 91-year history. Scaffolding is already up ...

As part of the transaction, Trond Waerness, Co-Founder of eStrat, joins Apollo Care's leadership team. Waerness brings deep domain expertise and long--standing experience supporting pharmaceutical ...

Apollo Care, which is backed by Flexpoint Ford, has acquired eStrat, a Raleigh, North Carolina-based copay and patient access ...

Honored at the three-day wellness conference, Bhaskar advanced nursing leadership while expanding scalable care delivery.

That's one small step for a man. One very expensive leap for the United States. Okay, sure, some would argue focusing on the total cost of the Apollo program defeats the purpose. Stepping onto the ...

Apollo Global Management Inc. is partnering with venture capital firm 8VC on a new business to bring private capital to technology companies working in industries including aerospace and energy.

Apollo Global is set to report Q3 results on November 4, with shares down 24% year-to-date. Q3 is expected to be above average for all three segments of Apollo. Apollo trades within its fair value ...

Alison Habens does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Celebrating 20 years, the Apollo EVO redefines hypercar exclusivity with only 10 track-only units. Set for 2026 delivery, it’s a collector’s dream, reviving Apollo’s Nürburgring legacy with unmatched ...

Forbes contributors publish independent expert analyses and insights. Sam Leveridge is a reporter based in Spain with a focus on soccer. The American private equity firm Apollo Global Management is ...

Private equity giant Apollo Global Management is reportedly weighing a sale of AOL after receiving unsolicited bids that could value the onetime internet pioneer at around $1.5 billion. Talks are in ...

Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis (AD). The phase 2a study involved ...